<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Overview of pregnancy termination
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Overview of pregnancy termination
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Overview of pregnancy termination
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jody Steinauer, MD, MAS, PhD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Rajita Patil, MD, FACOG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Cassing Hammond, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 07, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Access to safe abortion care and family planning services is an integral component of health care. This topic will review general issues regarding pregnancy termination, including preprocedure evaluation, choice of method, and complications. Techniques for first- and second-trimester procedures are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H636148010">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         A variety of terms are used to describe pregnancy termination, which can lead to confusion for clinicians and patients. We take the following approach to terminology:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pregnancy termination
         </strong>
         – Pregnancy termination may be used interchangeably with the term abortion. Other qualifiers (eg, "elective"), however, are often unnecessary and perpetuate the stigma associated with abortion care.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication abortion
         </strong>
         – Medication abortion is the termination of pregnancy by using medications to induce a process similar to a miscarriage. Less preferred terms include medical abortion, induced abortion, or induction abortion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedural abortion
         </strong>
         – Procedural abortion is the termination of pregnancy by uterine aspiration or dilation and evacuation (D&amp;E). Less preferred terms include surgical abortion or aspiration abortion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gestational age
         </strong>
         – Our topics use the term "gestational age," which is consistent with verbiage used by the American College of Obstetricians and Gynecologists (ACOG). However, other organizations (eg, Planned Parenthood Federation of America [PPFA], Society of Family Planning [SFP]) have transitioned to the term "gestational duration."
        </p>
        <p>
        </p>
        <p>
         Other terminology, including "unsafe" abortion, "abortion later in pregnancy," and "septic abortion," as well as terminology to describe pregnancy loss, are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14192.html" rel="external">
          "Unsafe abortion", section on 'Definitions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130878.html" rel="external">
          "Septic abortion: Clinical presentation and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5439.html" rel="external">
          "Pregnancy loss (miscarriage): Terminology, risk factors, and etiology", section on 'Terminology of pregnancy loss'
         </a>
         .)
        </p>
        <p>
         We also recognize and validate that people of all genders need access to abortion. Gender-neutral language in discussions of abortion care can be important in reflecting this reality [
         <a href="#rid1">
          1
         </a>
         ]. Throughout this article, we will use gendered language only if it reflects language used by authors in published studies, otherwise we will use "patients," "pregnant people," "people accessing abortion," and other inclusive terms.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 121 million unintended pregnancies occurred between 2015 and 2019, which constitutes 64 unintended pregnancies per 1000 reproductive-age females [
         <a href="#rid2">
          2
         </a>
         ]. Of these individuals, 61 percent underwent termination, resulting in a global abortion rate of 39 abortions per 1000 reproductive-age females. The highest rate was in West Africa (53 per 1000) and the lowest rate was in Australia/New Zealand (15 per 1000); rates in North America and Europe were 17 per 1000 [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         In the United States in 2020, the rate of pregnancy termination was 14.4 per 1000 females ages 15 to 44 years; this represents a 1 percent increase in the rate of abortions in such patients from 2017 to 2020 [
         <a href="#rid3">
          3
         </a>
         ]. However, the overall rate of abortion has decreased steadily over the past two decades. Other data specific to the United States from the Centers for Disease Control and Prevention (CDC) in 2018 include [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Abortion rates by age group
         </strong>
         – Abortion rates were highest for ages 20 to 24 (19.1 per 1000 females) and 25 to 29 (18.5 per 1000 females). The rate of abortion in adolescents was 6 per 1000 females for those ages 15 to 19 compared with 0.4 per 1000 females for those ages &lt;15 years.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Impact of specific demographic factors
         </strong>
         – Most terminations were in patients who had one or more children (59 percent). Forty percent of abortions were in patients who had a prior abortion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Racial disparities
         </strong>
         – Abortion rates per 1000 females by racial and ethnic groups were 6.3 for non-Hispanic White Americans, 21.2 for non-Hispanic Black Americans, and 10.9 for Hispanic American females.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distribution by age of gestation
         </strong>
         – The vast majority of pregnancy terminations were performed in the first trimester: 78 percent at ≤9 weeks and 92 percent at ≤13 weeks of gestation. For later gestational ages, 6.9 percent of abortions were performed at 14 to 20 weeks and 1 percent at ≥21 weeks.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Potential barriers to early abortion include delay in recognition and confirmation of pregnancy, maternal or fetal complications that are diagnosed or develop after the first trimester, expense, parental involvement laws (see
         <a class="local">
          'Legal issues'
         </a>
         below), and lack of access to an abortion provider [
         <a href="#rid5">
          5
         </a>
         ]. Among all United States counties in 2014, 90 percent had no abortion provider [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Distribution of procedure type
         </strong>
         – In 2017, medication abortion accounted for approximately 39 percent of all abortions and approximately 60 percent of abortions at &lt;10 weeks [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1278446806">
         <span class="h1">
          COUNSELING AND INFORMED CONSENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Counseling should include a nondirective discussion of alternatives (ie, continuing pregnancy with parenting or adoption) and a thorough discussion of the medical and procedural options for pregnancy termination, including the risks, benefits, and expected outcome of each. (See
         <a class="medical medical_review" href="/z/d/html/114587.html" rel="external">
          "Counseling in abortion care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2190635166">
         <span class="h2">
          Legal issues
         </span>
         <span class="headingEndMark">
          —
         </span>
         Abortion providers should be aware of relevant federal and state abortion regulations so they can provide appropriate treatment for their patients.
        </p>
        <p>
         In the United States in 2022, one year after the Supreme Court Dobbs v Jackson decision, 13 states completely banned abortion and many other states considered bans and other extreme restrictions [
         <a href="#rid8">
          8
         </a>
         ]. Some states have even proposed limiting the ability to travel out of state to obtain abortions. Even states lacking outright bans have mandatory waiting times between when the patient is counseled and the actual procedure, require parental notification or consent for abortions in minors (minors have the right to seek a court order authorizing the procedure) [
         <a href="#rid7">
          7
         </a>
         ], or mandate that specific topics (some of which are medically inaccurate) be covered in the counseling session. States with these legal restrictions, in addition to areas with limited access to available services, are associated with decreased rates of abortion [
         <a href="#rid5">
          5,9
         </a>
         ] and higher rates of abortion-related maternal mortality than states without these restrictions [
         <a href="#rid10">
          10
         </a>
         ]
         <em>
          .
         </em>
         These restrictions may also disproportionately affect vulnerable populations (eg, patients of lower socioeconomic status who may not be able to travel, pregnant minors, patients with mental disorders or cognitive disabilities, underrepresented groups) [
         <a href="#rid11">
          11-13
         </a>
         ]. A summary of United States abortion laws can be found through the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.guttmacher.org%2Fstate-policy%2Fexplore%2Foverview-abortion-laws&amp;token=FJhSE8QoN1cupcuBGJncsyaqELv7FJ0cypCQ4suUsYg4VWPW8aR9YzI5pzoVCVOLL8iYYaOBSq3W5L0oL7k65UrHeJY4hgPuYlhmnvPZo%2Bc%3D&amp;TOPIC_ID=3313" target="_blank">
          Guttmacher Institute
         </a>
         .
        </p>
        <p class="headingAnchor" id="H2859077804">
         <span class="h2">
          REMS restrictions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In the United States,
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         (a progesterone receptor antagonist used for medication abortion, second trimester procedural abortion, and management of pregnancy loss) is available only with Risk Evaluation and Mitigation Strategy (REMS) restrictions [
         <a href="#rid14">
          14
         </a>
         ]. Among many mandates, such restrictions require that mifepristone be prescribed only by a mifepristone REMS-registered health care provider (obtained by completing a mifepristone prescriber agreement form [
         <a href="#rid15">
          15,16
         </a>
         ]). Furthermore, mifepristone may be dispensed only by, or under the supervision of, a registered prescriber or by a registered pharmacy based on a prescription issued by a registered prescriber. Until 2023, this was limited to registered mail-order pharmacies and provider clinics. In January 2023, the US Food and Drug Administration (FDA) expanded access by allowing mifepristone prescriptions from a registered prescriber to be filled and dispensed by any mifepristone-registered retail pharmacy [
         <a href="#rid17">
          17
         </a>
         ]. Depending on state abortion bans and restrictions, this expansion may increase patient access to mifepristone especially for those seeking alternative methods to in-person care (eg, telemedicine, hybrid models). (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Telemedicine and hybrid models'
         </a>
         .)
        </p>
        <p>
         However, such restrictions may not reduce adverse events or abortion rates. In a retrospective study including over 300,000 abortions performed in Canada, those performed before and after
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         was available and with and without REMS-like restrictions had similarly low rates of severe adverse events (eg, blood transfusion, abdominal surgery, admission to an intensive care unit, sepsis) and other complications [
         <a href="#rid18">
          18
         </a>
         ]. In addition, while the rate of medication abortion increased after REMS-like restrictions were lifted, the overall rate of abortion remained stable.
        </p>
        <p class="headingAnchor" id="H3133425816">
         <span class="h1">
          DETERMINING GESTATIONAL AGE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Determining the correct gestational age is a critical part of preabortion care and can be obtained by menstrual dating or pelvic ultrasound examination.
        </p>
        <p class="headingAnchor" id="H3169041925">
         <span class="h2">
          Menstrual dating
         </span>
         <span class="headingEndMark">
          —
         </span>
         Menstrual dating can be used in patients in whom the first day of the last menstrual period (LMP) is known with certainty and in those with regular menstrual cycles. When menstrual dating is used, the gestational age is estimated based on the interval from the LMP and, prior to procedural abortion, is confirmed by bimanual examination and/or ultrasound.
        </p>
        <p>
         Evidence shows that in patients with regular menstrual cycles and a known LMP, gestational age as predicted by menstrual dating compared with ultrasound dating are similar [
         <a href="#rid19">
          19,20
         </a>
         ]. In a systematic review including three studies comparing determination of gestational age by LMP or ultrasound, 2.5 to 11 percent of patients who were eligible for medication abortion by LMP became ineligible after ultrasound evaluation [
         <a href="#rid19">
          19
         </a>
         ]; lower rates were reported when gestation was &lt;63 days (63 of 4008 [1.6 percent] patients; one study) [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5391.html" rel="external">
          "Prenatal assessment of gestational age, date of delivery, and fetal weight", section on 'Clinical assessment of gestational age'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1208692352">
         <span class="h2">
          Role of pelvic ultrasound examination
         </span>
         <span class="headingEndMark">
          —
         </span>
         While pelvic ultrasound examination may be helpful and is commonly used by abortion providers in the United States, it is
         <strong>
          not
         </strong>
         a requirement for first-trimester abortion, and most abortion care outside of the United States is without ultrasound. The clinical policy guidelines of the National Abortion Federation (NAF), a professional organization of abortion providers in the United States, Canada, Mexico, and Colombia, as well as the American College of Obstetrics and Gynecology (ACOG) and World Health Organization (WHO), do not mandate ultrasound preceding abortion in the first trimester since doing so is not always necessary or even helpful and might impede access to abortion in underserved regions where ultrasound is unavailable [
         <a href="#rid22">
          22-24
         </a>
         ].
        </p>
        <p>
         Ultrasound examination is useful if patients are uncertain of their dates, have irregular periods, their uterine size is inconsistent with menstrual dates, or their uterine size cannot be adequately assessed. Ultrasound is also used to diagnose ectopic and nonviable pregnancies. (See
         <a class="medical medical_review" href="/z/d/html/5391.html" rel="external">
          "Prenatal assessment of gestational age, date of delivery, and fetal weight", section on 'Sonographic assessment of gestational age'
         </a>
         and
         <a class="local">
          'Ectopic pregnancy'
         </a>
         below.)
        </p>
        <p>
         We perform a preprocedural ultrasound prior to all second-trimester abortions.
        </p>
        <p class="headingAnchor" id="H15895836">
         <span class="h1">
          CHOICE OF PROCEDURE
         </span>
         <span class="headingEndMark">
          —
         </span>
         The choice of procedure type (ie, medication, surgery) depends on gestation, patient preferences, clinician experience, availability of services, and legislative barriers. All options are safe and effective for appropriately selected patients.
        </p>
        <p class="headingAnchor" id="H3815503277">
         <span class="h2">
          First trimester
         </span>
        </p>
        <p class="headingAnchor" id="H2288545082">
         <span class="h3">
          How to choose
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ideally, patients seeking first-trimester abortion care should have access to both medication and procedural abortion and be counseled about the benefits and limitations of each. Factors that contribute to this choice include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gestational age
         </strong>
         – The US Food and Drug Administration (FDA) approves
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         in combination with
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         for medication abortion up to 70 days (≤10 weeks) of gestation [
         <a href="#rid25">
          25
         </a>
         ]. The National Abortion Federation (NAF) and Planned Parenthood Federation of America support its use up to 77 days (11 weeks) [
         <a href="#rid22">
          22
         </a>
         ]. Patients &gt;11 weeks are not currently eligible for first-trimester medication abortion with mifepristone. Misoprostol-only regimens (which have lower efficacy) may be used in settings in which mifepristone is not available or is too costly. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5434.html" rel="external">
          "Misoprostol as a single agent for medical termination of pregnancy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Aspiration abortion is most common through 14 weeks of gestation; more advanced gestations usually require initial use of vacuum aspiration followed by use of forceps after cervical dilation (ie, dilation and evacuation [D&amp;E]). (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Are there contraindications to either approach?
         </strong>
         – Contraindications to medication (eg, hemoglobin ≤9 g/dL, hemorrhagic disorders) and procedural abortion (eg, fibroid restricting access to the uterine cavity) are discussed separately. (See
         <a class="local">
          'Laboratory testing'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Contraindications'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Patient selection'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient preference
         </strong>
         – The main factor affecting choice of procedure is patient experience.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Factors favoring medication
         </strong>
         – Medication abortion allows the patient to avoid a procedure and anesthesia, and some patients feel that the process seems more "natural." Some patients prefer medication abortion because they feel they have a greater degree of control over the process as they manage the procedure privately within their own home [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In addition, patients may feel more empowered with telemedicine rather than in-person medication abortion, allowing for increased convenience and privacy [
         <a href="#rid27">
          27-33
         </a>
         ]. Patients with specific socioeconomic or personal concerns (eg, privacy, convenience, limited access to in-person care) may also prefer telemedicine rather in-person medication abortion [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Factors favoring uterine aspiration
         </strong>
         – The uterine aspiration procedure takes place at a health care facility, is typically completed in less than 15 minutes, is performed under local anesthesia and/or sedation, and, greater than 99 percent of the time, allows patients to leave the visit knowing that the abortion is complete (see
         <a class="local">
          'Relative outcomes'
         </a>
         below). By contrast, medication abortion takes longer, has a slightly lower efficacy, and patients may have a greater awareness of blood loss and passage of pregnancy tissue, particularly at later gestations [
         <a href="#rid36">
          36
         </a>
         ]; for some patients, awareness of these aspects of the process may lead them to choose aspiration abortion.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Some socioeconomic or personal concerns (eg, housing instability, poor social support, upcoming travel) may make uterine aspiration a favored choice due to shorter and more predictable vaginal bleeding compared with medication abortion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients place significant value on the option to choose between medication and aspiration abortion [
         <a href="#rid37">
          37
         </a>
         ]. In studies where patients are allowed a choice between abortion methods, 35 to 84 percent chose medication abortion. Most patients who select medication abortion report they would opt for medication abortion again (63 to 96 percent) if they had another abortion in the future [
         <a href="#rid38">
          38
         </a>
         ]. When looking at choices between in-person and telemedicine abortion, patients who choose a telemedicine medication abortion are more likely to choose telemedicine again [
         <a href="#rid28">
          28
         </a>
         ] or recommend the service to a friend [
         <a href="#rid27">
          27
         </a>
         ] compared with those who had in-person visits [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H860168476">
         <span class="h3">
          Procedure setting
         </span>
         <span class="headingEndMark">
          —
         </span>
         While medication abortion was traditionally an in-person, clinic-based service, more patients are accessing telemedicine or hybrid services, or are self-managing their abortion.
        </p>
        <p class="headingAnchor" id="H55284746">
         <span class="h4">
          In-person
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication abortion
         </strong>
         – In-person medication abortion is used for patients who have access to or desire in-person care, or those not eligible for an abortion facilitated outside of a clinic setting (ie, telehealth, self-managed abortion [SMA]). (See
         <a class="local">
          'Telemedicine'
         </a>
         below and
         <a class="local">
          'Self-managed'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'In-person'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aspiration abortion
         </strong>
         – Aspiration abortion is typically performed in an outpatient setting, such as in a clinic, a clinician's office equipped with a procedure room, or an ambulatory surgery center, but sometimes occurs in a hospital-based procedure or operating room. (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Procedure setting'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2591030728">
         <span class="h4">
          Telemedicine
         </span>
         <span class="headingEndMark">
          —
         </span>
         During the coronavirus disease 2019 (COVID-19) pandemic, when access to medical care was limited, clinicians increased efforts to expand access to medication abortion without requiring in-person visits. In these settings, an eligible patient (eg, known last menstrual period [LMP], no risk factors for ectopic pregnancy  (
         <a class="graphic graphic_table graphicRef82282" href="/z/d/graphic/82282.html" rel="external">
          table 1
         </a>
         ), no contraindications to medication abortion) can receive a medication abortion without receiving in-person care. Such patients do not receive a pre- or posttreatment ultrasound, laboratory testing, or physical examination; this is termed a "no-test," or "history-based," abortion. Counseling and assessment occur online, or by video or phone, and medications are dispensed by curbside pickup or mail. Hybrid models, where components of the medication abortion visit are completed via telemedicine and other components (eg, picking up medications) in the clinic, also occur. (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Telemedicine and hybrid models'
         </a>
         .)
        </p>
        <p>
         These models have been shown to be equally safe and effective as the traditional clinic medication abortion model. (See
         <a class="local">
          'Relative outcomes'
         </a>
         below.)
        </p>
        <p>
         With increasing restrictions to abortion access in the United States, utilization of this method is increasing [
         <a href="#rid39">
          39
         </a>
         ]. In one retrospective study of patients receiving medication abortion, those choosing telemedicine compared with an in-person setting were more likely to live further from an abortion clinic and have had at least one prior abortion [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H529998946">
         <span class="h4">
          Self-managed
         </span>
         <span class="headingEndMark">
          —
         </span>
         With increasing restrictions on abortion access in the United States (ie, after the overturn of Roe v Wade in 2022), more patients are also choosing self-managed abortion (SMA; when accessing medication abortion, it is also referred to as self-managed medication abortion [SMMA]). In an SMA, a patient accesses abortion and abortion medications outside of a clinical interaction, often through the internet, without interacting with or supervision from a clinician. This model has also been shown to be safe and effective [
         <a href="#rid41">
          41-43
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Self-managed'
         </a>
         .)
        </p>
        <p>
         Unsafe approaches to self-induce abortions, including usage of herbs, vaginal insertion of objects, and abdominal trauma [
         <a href="#rid44">
          44-47
         </a>
         ], are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14192.html" rel="external">
          "Unsafe abortion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H644011227">
         <span class="h3">
          Relative outcomes
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          According to procedure type
         </strong>
         – Aspiration abortion is slightly more effective than medication abortion as it results in termination of pregnancy in over 99 percent of procedures [
         <a href="#rid48">
          48,49
         </a>
         ]. The success rate of medication abortion with
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         and
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         is 95 to 98 percent, with 2 to 5 percent of cases requiring further intervention with repeat misoprostol or suction dilation and curettage for retained tissue or continuing pregnancy [
         <a href="#rid50">
          50,51
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overall, complications are more common in medication abortion than in aspiration abortion, driven largely by the need for aspiration to treat retained tissue or ongoing pregnancy [
         <a href="#rid49">
          49,52-54
         </a>
         ]. Representative studies include the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a state-level, insurance claims-based study that captured all emergency department visits following 50,000 abortion procedures, complication rates were higher following medication compared with aspiration abortion [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a retrospective study including 30,146 patients undergoing first-trimester pregnancy termination at a large abortion clinic, the efficacy of pregnancy termination was 99.6 percent for medication abortion (which included cases that required repeat
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         or uterine aspiration for initially incomplete procedures) and 99.8 percent for the aspiration abortion group. Patients in the medication abortion group were more likely to undergo an unanticipated aspiration for ongoing pregnancy or persistent pain, bleeding, or both (2.1 compared with 0.6 percent, respectively) [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a cohort study using administrative health databases and including over 100,000 patients undergoing first-trimester pregnancy termination, those undergoing medication abortion (38 percent) compared with uterine aspiration had higher rates of serious adverse events (3.3 versus 1.8 per 1000; relative risk [RR] 1.9, 95% CI 1.4-2.4) within 42 days of the procedure [
         <a href="#rid55">
          55
         </a>
         ]. Patients undergoing medication abortion were also more likely to have an emergency department visit (RR 1.2, 95% CI 1.1-1.3) and an unplanned aspiration procedure (3.4, 95% CI 2.7-4.3). The reason for the emergency department visit was not reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          According to procedure setting
         </strong>
         – Outcomes according to procedure setting (eg, telemedicine, ambulatory surgery center, office-based setting) are similar.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a study including over 50,000 abortions (all types) from a United States private insurance database, the incidence of adverse events was comparable for procedures performed in either an ambulatory surgery center or office-based setting [
         <a href="#rid56">
          56
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Large observational studies have also shown that no-test (ie, history-based) abortion is equally effective and safe as clinic-based medication abortion [
         <a href="#rid27">
          27,41,57-66
         </a>
         ]. In the largest retrospective study including over 52,000 patients undergoing pregnancy termination in the United Kingdom, patients undergoing telemedicine compared with traditional clinic-based medication abortion had similar rates of treatment success (98 percent) and adverse outcomes; major complications were uncommon [
         <a href="#rid63">
          63
         </a>
         ]. In a subsequent multicenter, retrospective study in the United States including almost 2400 patients undergoing history-based medication abortion in whom follow-up data were available, initial treatment success occurred in 95 percent of patients; 125 patients (5 percent) required either an additional procedure (eg, uterine aspiration, additional medication, treatment for ectopic pregnancy) or had a continuing pregnancy at the last point of study-contact [
         <a href="#rid67">
          67
         </a>
         ]. Abortion-related adverse events were rare.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         A more detailed discussion of potential complications associated with medication and procedural abortion is provided below. (See
         <a class="local">
          'Complications'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2706888061">
         <span class="h2">
          Second trimester
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to first-trimester abortion, second-trimester procedures can be performed with induction (medication) or surgery (D&amp;E). How to choose between procedure types, procedure setting (eg, outpatient facility, labor and delivery unit), and the relative outcomes of each are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1702364084">
         <span class="h1">
          PREPARATION FOR PROCEDURE
         </span>
        </p>
        <p class="headingAnchor" id="H3327838278">
         <span class="h2">
          Laboratory testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The World Health Organization (WHO) does
         <strong>
          not
         </strong>
         require any laboratory testing be performed for an abortion [
         <a href="#rid24">
          24
         </a>
         ].
         <strong>
         </strong>
         Laboratory testing that may be performed in selected patients includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urine or serum human chorionic gonadotropin (hCG) measurement
         </strong>
         – Urine hCG is often used to confirm pregnancy; if there is concern for an abnormal pregnancy (eg, ectopic), serum hCG should be determined. A patient's own positive home urine pregnancy test may be used as pregnancy confirmation and does not require repetition.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The various types of urine or serum hCG tests are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/440.html" rel="external">
          "Clinical manifestations and diagnosis of early pregnancy", section on 'Types of pregnancy tests'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemoglobin or hematocrit
         </strong>
         – In our practice:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients at ≤9 weeks, we only check hemoglobin or hematocrit if the patient has a history of anemia (and no result is available from the past 6 to 12 months) or if we are drawing blood for another indication (hCG or Rh typing). If drawn for a patient with a history of anemia, there is no definitive cutoff value at which we prefer a procedural, rather than medication, abortion, and the decision is left to the discretion of the provider. If the patient has a hemoglobin drawn because other laboratory tests are indicated, we do not wait for the result before providing the medication abortion or discharging the patient from clinic.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients ≥10 weeks, we test routinely and wait for the results; hemoglobin values ≤9 g/dL are considered a relative contraindication to a medication abortion (given the increased risk for a clinically significant drop in hemoglobin at this gestation), and a procedural abortion is recommended.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          RhD typing
         </strong>
         – While RhD status was historically performed on all patients, evidence shows risk of alloimmunization of D-negative patients to be negligible for gestations &lt;12 weeks [
         <a href="#rid68">
          68-72
         </a>
         ]. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients", section on 'Selective prophylaxis for pregnancy complications associated with fetomaternal bleeding'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our practice regarding Rh typing is to follow the WHO, Society of Family Planning (SFP), and National Abortion Federation (NAF) guidelines and
         <strong>
          not
         </strong>
         perform RhD testing for patients &lt;12 weeks gestation  (
         <a class="graphic graphic_table graphicRef140124" href="/z/d/graphic/140124.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid24">
          24,73-75
         </a>
         ]. By contrast, the American College of Obstetrics and Gynecology (ACOG) recommends that all RhD-negative patients undergoing pregnancy termination receive
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         to prevent alloimmunization, regardless of gestational age; shared decision making should be used when testing/administration are not available or would delay the procedure [
         <a href="#rid23">
          23
         </a>
         ]. (See
         <a class="local">
          'Alloimmunization prevention'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chlamydia and/or gonorrhea
         </strong>
         – Screening for chlamydia and gonorrhea should be based on the United States Preventive Services Task Force and Centers for Disease Control and Prevention (CDC) guidelines, which recommend screening of all sexually active patients &lt;25 years old and patients at increased risk of infection, regardless of age. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections", section on 'Females'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, we do not routinely perform chlamydia and gonorrhea testing for patients without symptoms in whom medication abortion is planned.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1161120300">
         <span class="h2">
          Alloimmunization prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         All RhD-negative patients undergoing pregnancy termination have traditionally received
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         to prevent alloimmunization. While this concurs with the approach taken by United States and Canadian guidelines [
         <a href="#rid76">
          76,77
         </a>
         ], not all experts agree, and some organizations recommend
         <strong>
          against
         </strong>
         anti-D globulin administration for gestations that are &lt;12 weeks of gestation (WHO [
         <a href="#rid24">
          24
         </a>
         ], SFP [
         <a href="#rid74">
          74
         </a>
         ], NAF [
         <a href="#rid75">
          75
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef140124" href="/z/d/graphic/140124.html" rel="external">
          table 2
         </a>
         )). This is because the risk for alloimmunization has been shown to be negligible in such patients [
         <a href="#rid68">
          68-72
         </a>
         ]. In other countries, guidelines vary regarding whether anti-D immune globulin is required for first-trimester spontaneous abortion. Studies of unsensitized D-negative patients undergoing first-trimester abortion are sparse and data are presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients"
         </a>
         .)
        </p>
        <p>
         When anti-D globin is given, a dose of 50 mcg is effective through the 12
         <sup>
          th
         </sup>
         week of gestation (due to the small volume of red cells in the fetoplacental circulation), and a dose of 100 mcg is effective from the 13
         <sup>
          th
         </sup>
         through the 18
         <sup>
          th
         </sup>
         week of gestation [
         <a href="#rid74">
          74
         </a>
         ]. However, there is no harm in giving the standard 300 mcg dose, which is more readily available [
         <a href="#rid76">
          76,77
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6773.html" rel="external">
          "RhD alloimmunization: Prevention in pregnant and postpartum patients", section on 'Anti-D immune globulin'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1815757609">
         <span class="h2">
          Cervical dilation and preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Mechanical dilation of the cervix at the time of procedural aspiration, to allow insertion of instruments and removal of the products of conception, is usually necessary after 8 weeks of gestation and sometimes for earlier gestations. Cervical preparation with osmotic dilators and/or prostaglandins is typically used prior to aspiration abortions performed after 12 to 14 weeks of gestation. This is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/111284.html" rel="external">
          "Pregnancy termination: Cervical preparation for procedural abortion"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">
          "Second-trimester pregnancy termination: Induction (medication) termination", section on 'Cervical dilation'
         </a>
         .)
        </p>
        <p>
         Cervical dilation and/or preparation is not used prior to medication abortion.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Antibiotic prophylaxis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of antibiotic prophylaxis varies by procedure type and other factors; this is discussed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Limited role of prophylactic antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Antibiotic prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">
          "Second-trimester pregnancy termination: Dilation and evacuation", section on 'Prophylactic antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">
          "Second-trimester pregnancy termination: Induction (medication) termination", section on 'Prophylactic antibiotics'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1576010917">
         <span class="h2">
          Pain management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pain management varies by procedure type. For example, nonsteroidal antiinflammatory drugs, with or without oral narcotics, are often used for first-trimester medication abortions, while patients undergoing a second-trimester abortion may receive a paracervical block and intravenous conscious sedation prior to a dilation and evacuation (D&amp;E) or an epidural prior to a medication induction. This is discussed in detail separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/104595.html" rel="external">
          "Second-trimester pregnancy termination: Dilation and evacuation", section on 'Anesthesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90163.html" rel="external">
          "Second-trimester pregnancy termination: Induction (medication) termination", section on 'Anesthesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2184620175">
         <span class="h2">
          Guidelines for staff and equipment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The National Abortion Federation (NAF) has issued
         <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fprochoice.org%2Fwp-content%2Fuploads%2F2014NAFCPGs.pdf&amp;token=xpScufR%2BLN173%2FwSYmqLfYG2UiJaSvDiZBmmnHXymjS4xrd6p7dqdJPs2Q7plNDalSpsWzViCcsgolA31fYNFA%3D%3D&amp;TOPIC_ID=3313" target="_blank">
          clinical policy guidelines
         </a>
         regarding medical personnel and facilities that provide pregnancy termination care [
         <a href="#rid78">
          78
         </a>
         ]. These stipulate, for example, that abortions should be provided by a licensed practitioner. Training programs, such as the
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fryanprogram.org%2F&amp;token=872Mez%2FzqQDb2TPbCcezmNazT36V%2FvSTYqNVFlkDL%2FGvALUkLBSw0hah5bEtTSir&amp;TOPIC_ID=3313" target="_blank">
          Ryan Program
         </a>
         and Patient-Centered Abortion Care Education (PACE) curriculum, are available to support abortion training among obstetrics and gynecology physicians [
         <a href="#rid79">
          79,80
         </a>
         ].
        </p>
        <p>
         The minimum requirements for a facility include on-site presence of a medical staff member with updated basic life support certification; an oxygen delivery system, oral airways, self-inflating respirator bags, and bronchodilators; and uterotonics and vasopressors, including
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         . In settings in which opioids or benzodiazepines are used, appropriate antagonists must be available.
        </p>
        <p>
         It is useful for outpatient clinics to have written protocols to address emergencies, particularly indications for emergency transport to a hospital and contact information for personnel who are immediately available to facilitate transport.
        </p>
        <p class="headingAnchor" id="H2087420230">
         <span class="h2">
          Plan for contraception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ovulation can occur soon after an abortion and before the onset of menses; thus, we recommend that contraception counseling is offered prior to the abortion procedure. Contraception can usually be initiated the day of the procedure, with the exception of IUD placement before a medication abortion is complete. (See
         <a class="medical medical_review" href="/z/d/html/109209.html" rel="external">
          "Contraception: Postabortion", section on 'Initiation of contraception'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3496663816">
         <span class="h1">
          FOLLOW-UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         After pregnancy termination, patients may experience vaginal bleeding that is comparable to a menstrual period and that decreases over time; passage of small clots of blood from the vagina may also occur. Patients may experience mild lower abdominal cramping, which can be treated with nonsteroidal antiinflammatory drugs. The provider should be called for bleeding heavier than a normal period, fever ≥38°C (≥100.4°F), or if more severe abdominal pain develops. Postprocedure care and instructions are provided in writing and reviewed verbally  (
         <a class="graphic graphic_table graphicRef126344" href="/z/d/graphic/126344.html" rel="external">
          table 3
         </a>
         ). Historically, patients have been counseled to avoid vaginal intercourse and use of tampons for two weeks after the procedure to reduce the risk of infection. However, these instructions are not evidence-based and are no longer advised by the authors.
        </p>
        <p>
         For patients in whom posttermination human chorionic gonadotropin (hCG) levels are followed (eg, products of conception not visible after first-trimester uterine aspiration, patients in whom ectopic pregnancy is a concern), an elevated level of hCG is expected for a short period of time. Return of the serum hCG concentration to undetectable following pregnancy termination varies widely from 7 to 60 days [
         <a href="#rid81">
          81
         </a>
         ]. The duration depends primarily on the hCG concentration at the time of termination. The decline in serum hCG is rapid for the first several days (half-life 9 to 31 hours) and then proceeds more slowly (half-life 55 to 64 hours) [
         <a href="#rid82">
          82-84
         </a>
         ]. (See
         <a class="local">
          'Ectopic pregnancy'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/3209.html" rel="external">
          "Human chorionic gonadotropin: Biochemistry and measurement in pregnancy and disease"
         </a>
         .)
        </p>
        <p>
         Specific follow-up details, as they relate to trimester and procedure type, are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Recovery and follow-up'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination", section on 'Postprocedure considerations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h1">
          COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3534975681">
         <span class="h2">
          Overall
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rate of complications associated with pregnancy termination depends on the procedure type, gestation, patient characteristics, and clinician experience. In general, the risk of a major complication is low. In a retrospective study of California Medicaid data from 54,911 abortion procedures, the overall complication rate was 2.1 percent [
         <a href="#rid54">
          54
         </a>
         ]. Rates of major (ie, hospital admission, surgery, transfusion) and minor complications were:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-trimester aspiration – Major 0.16 percent; minor 1.1 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medication abortion – Major 0.31 percent; minor 4.88 percent
        </p>
        <p>
        </p>
        <p>
         Complication rates may be higher in patients with medical conditions. In a study based on national United States inpatient data from 2000 to 2011 including over 38,000,000 patients who underwent a medically necessary abortion (defined as needed to protect a patient's health), the rate of severe maternal morbidity was 62.4 per 10,000 hospitalizations [
         <a href="#rid85">
          85
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Hemorrhage
         </span>
         <span class="headingEndMark">
          —
         </span>
         Postabortion hemorrhage occurs in less than 1 percent of abortions [
         <a href="#rid86">
          86
         </a>
         ]. Hemorrhage may result from uterine atony, cervical laceration, uterine perforation, or retained tissue. Other causes of postabortion hemorrhage include infection, enhanced myometrial vascularity, placenta accreta spectrum, vaginal laceration, and coagulopathy (secondary to release of tissue thromboplastin into the maternal venous system). Treatment of postabortion hemorrhage is similar to postpartum hemorrhage following vaginal birth. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management"
         </a>
         .)
        </p>
        <p>
         The Society of Family Planning guidelines advise the following general approach to postabortion hemorrhage [
         <a href="#rid86">
          86
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assessment and examination, including repair of bleeding cervical or vaginal lacerations and exploration (and evacuation) of the uterus for retained products of conception.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment of uterine atony with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uterine massage and compression. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Perform uterine massage and compression'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Uterotonic drugs (ie, oxytocin,
         <a class="drug drug_general" data-topicid="9637" href="/z/d/drug information/9637.html" rel="external">
          methylergonovine
         </a>
         maleate,
         <a class="drug drug_general" data-topicid="9203" href="/z/d/drug information/9203.html" rel="external">
          carboprost tromethamine
         </a>
         injection [commercial name Hemabate],
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ) are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6714.html" rel="external">
          "Postpartum hemorrhage: Medical and minimally invasive management", section on 'Administer additional uterotonic medications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intrauterine tamponade – When intrauterine tamponade is used, one method is to insert a Foley catheter into the uterine cavity and expand the 30 mL balloon with 50 to 60 mL
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         or water. Other types of intrauterine tamponade are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4440.html" rel="external">
          "Postpartum hemorrhage: Use of an intrauterine hemorrhage-control device", section on 'Types and efficacy'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Laboratory evaluation, including complete blood count and coagulation studies, and resuscitative measures (eg, fluid replacement, oxygenation, transfusion with blood products). (See
         <a class="medical medical_review" href="/z/d/html/6710.html" rel="external">
          "Overview of postpartum hemorrhage"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pelvic embolization may be used for treatment of hemorrhage if other measures are not successful and the patient is stable [
         <a href="#rid87">
          87,88
         </a>
         ]. Bleeding that continues despite all other measures may require uterine artery ligation or hysterectomy, but this is rare after abortion.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h2">
          Uterine perforation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Uterine perforation is rare, occurring in fewer than 0.3 percent of first- and second-trimester procedural abortions [
         <a href="#rid86">
          86
         </a>
         ]. Suspected uterine perforation requires further evaluation. The specific location of a uterine perforation determines the symptoms and degree of hemorrhage.
        </p>
        <p>
         Two factors associated with an increased risk of perforation during pregnancy termination are surgeon inexperience (residents have a 5.5-fold increase in perforations as compared with attending staff) and lack of adequate preoperative cervical dilation [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p>
         Uterine perforation is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3309.html" rel="external">
          "Uterine perforation during gynecologic procedures"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1263571835">
         <span class="h2">
          Ongoing pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ongoing pregnancy is more likely to be a complication of early rather than late abortion and is more common in patients undergoing medication rather than procedural abortion. It occurs in approximately 0.5 percent of medication (ie,
         <a class="drug drug_general" data-topicid="10263" href="/z/d/drug information/10263.html" rel="external">
          mifepristone
         </a>
         plus
         <a class="drug drug_general" data-topicid="9657" href="/z/d/drug information/9657.html" rel="external">
          misoprostol
         </a>
         ) abortions [
         <a href="#rid53">
          53
         </a>
         ]. (See
         <a class="local">
          'Relative outcomes'
         </a>
         above.)
        </p>
        <p>
         When procedural abortion is performed, products of conception should be closely examined by an experienced clinician to verify successful completion. Although rare, ongoing pregnancy may result from a multiple gestation in which only one of the sacs was removed. (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Tissue evaluation'
         </a>
         .)
        </p>
        <p>
         The type and risk of possible damage to the ongoing pregnancy from an attempted abortion is unclear. Direct or indirect injury to the developing embryo may occur. (See
         <a class="medical medical_review" href="/z/d/html/3287.html" rel="external">
          "First-trimester pregnancy termination: Uterine aspiration", section on 'Incomplete or failed abortion'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3296.html" rel="external">
          "First-trimester pregnancy termination: Medication abortion", section on 'Teratogenicity'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5434.html" rel="external">
          "Misoprostol as a single agent for medical termination of pregnancy", section on 'Teratogenicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H31">
         <span class="h2">
          Infection/retained products of conception
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sepsis after pregnancy termination is rare and is suggested by generalized abdominal tenderness, guarding, tachycardia, and high fever. These patients require aggressive therapy with broad-spectrum intravenous antibiotics, prompt assessment for retained products of conception and removal if present, evaluation for uterine perforation, and monitoring and support in an intensive care unit. (See
         <a class="medical medical_review" href="/z/d/html/130878.html" rel="external">
          "Septic abortion: Clinical presentation and management"
         </a>
         .)
        </p>
        <p>
         Postabortion endometritis is also uncommon and occurs in &lt;1 percent of patients [
         <a href="#rid90">
          90
         </a>
         ]; this can occur either with or without retained gestational tissue. Signs and symptoms are similar for isolated endometritis and endometritis with retained products of conception and include fever, uterine tenderness, lower abdominal pain, and greater than expected uterine bleeding. Ultrasonography can evaluate for retained products in the uterine cavity. Any physical or sonographic evidence of retained products of conception should prompt consideration of suction curettage to complete evacuation of the uterus. (See
         <a class="medical medical_review" href="/z/d/html/5482.html" rel="external">
          "Retained products of conception in the first half of pregnancy"
         </a>
         .)
        </p>
        <p>
         In the absence of detectable retained material, a presumptive diagnosis of endometritis may be made and treated with a trial of broad-spectrum antibiotic therapy, with coverage of anaerobes (eg,
         <a class="drug drug_general" data-topicid="9222" href="/z/d/drug information/9222.html" rel="external">
          cefotetan
         </a>
         [2 grams intravenously] plus
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         [100 mg intravenously or orally] every 12 hours). This regimen can be completed as an outpatient oral regimen for a 14-day course. An alternative outpatient regimen is
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         250 mg intramuscularly in a single dose plus doxycycline 100 mg orally twice a day for 14 days with or without
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         500 mg orally twice a day for 14 days.
        </p>
        <p class="headingAnchor" id="H3170204460">
         <span class="h2">
          Maternal mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         The overall death rate from all legal abortions is far less than the maternal mortality ratio among live births in the United States  (
         <a class="graphic graphic_table graphicRef63961" href="/z/d/graphic/63961.html" rel="external">
          table 4
         </a>
         ) [
         <a href="#rid91">
          91-93
         </a>
         ]. Maternal mortality is lowest before 9 weeks of gestation and increases rapidly after 18 weeks of gestation (&lt;0.3 per 100,000 induced abortions at &lt;9 weeks versus 7 per 100,000 at 16 to 20 weeks and 11 per 100,000 at ≥21 weeks) [
         <a href="#rid92">
          92
         </a>
         ]. For counseling purposes, this risk of first-trimester pregnancy termination can be compared with other procedures, such as plastic surgery procedures (0.8 to 1.7 deaths per 100,000) or dental procedures (0 to 1.7 deaths per 100,000) [
         <a href="#rid91">
          91
         </a>
         ].
        </p>
        <p>
         Aspiration abortion has the lowest maternal mortality rate of any procedural pregnancy termination method. One study reported no maternal deaths in 170,000 consecutive first-trimester suction curettage procedures [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p>
         Countries with better training of and access to abortion providers have lower maternal mortality rates [
         <a href="#rid95">
          95
         </a>
         ]. This relationship is also true in the United States; states that have restricted abortion access have increasing maternal mortality while it is declining in states with improved access to abortion services [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H165526836">
         <span class="h1">
          SPECIAL CONSIDERATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H415446466">
         <span class="h2">
          Unsafe abortion
         </span>
         <span class="headingEndMark">
          —
         </span>
         Access to safe abortion care is an essential component of health care. Unfortunately, a large portion of abortions are considered "unsafe," and these abortions are a major contributor to both maternal morbidity and mortality. The risk of complications and death from unsafe abortion is inversely related to the provider's training [
         <a href="#rid96">
          96
         </a>
         ], skill, conditions for performing the procedure, and availability of appropriate equipment. Some unsafe abortions are self-induced; the consequences in these cases also depend on whether the patient has access to, or can seek, medical care. (See
         <a class="medical medical_review" href="/z/d/html/14192.html" rel="external">
          "Unsafe abortion"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3104521065">
         <span class="h2">
          Ectopic pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Ectopic pregnancy occurs in less than 1 percent of patients presenting for pregnancy termination [
         <a href="#rid97">
          97,98
         </a>
         ]; in the United States, this is approximately three times lower than the national rate of ectopic pregnancy [
         <a href="#rid99">
          99
         </a>
         ]. However, when it does occur, ectopic pregnancy can cause significant maternal morbidity and mortality. For any abortion performed with a pregnancy of unknown location (ie, no yolk sac or fetal pole noted on a pretreatment ultrasound), it is important to evaluate for risk of ectopic pregnancy  (
         <a class="graphic graphic_table graphicRef82282" href="/z/d/graphic/82282.html" rel="external">
          table 1
         </a>
         ). Ectopic pregnancy can be ruled out postabortion by either identifying products of conception after aspiration or by a postabortion serum human chorionic gonadotropin (hCG) level with a sharp decline from a baseline preabortion value. (See
         <a class="local">
          'Follow-up'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/5487.html" rel="external">
          "Ectopic pregnancy: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2855060216">
         <span class="h2">
          Future pregnancies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data regarding the association of pregnancy termination and subsequent adverse pregnancy outcomes (eg, preterm birth, low birth weight) are conflicting [
         <a href="#rid24">
          24,71,100-108
         </a>
         ]. Variables that may affect outcomes include study design, gestational age at time of termination, time period of the included studies (which may reflect changes in postabortion or pregnancy care), and procedure type.
        </p>
        <p>
         Future obstetric outcomes by procedure type are as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Procedural abortion
         </strong>
         – Procedural abortion may be associated with adverse pregnancy outcomes. In a meta-analysis including 31 studies (&gt;900,000 patients) with a history of procedural abortion compared with patients without uterus instrumentation, prior procedural abortion was associated with an increased risk of preterm birth, low birth weight, and small for gestational age (SGA) infants, although the absolute risk remained small [
         <a href="#rid104">
          104
         </a>
         ]. The reported outcomes were: preterm birth, 5.4 versus 4.4 percent, odds ratio (OR) 1.52, 95% CI 1.08-2.16; low birth weight, 7.3 versus 5.9 percent, OR 1.41, 95% CI 1.22-1.62; and SGA, 10.2 versus 9 percent, OR 1.19, 95% CI 1.01-1.42. (See
         <a class="medical medical_review" href="/z/d/html/6761.html" rel="external">
          "Spontaneous preterm birth: Overview of risk factors and prognosis", section on 'Past history of procedural abortion'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         By contrast, other series addressing future pregnancy in patients who underwent a prior procedural abortion do not show this association [
         <a href="#rid100">
          100,105,106,109
         </a>
         ]. In a retrospective review including 600 patients undergoing dilation and evacuation (D&amp;E) between 14 and 24 weeks, the overall rate of preterm birth in subsequent pregnancies was less than the overall rate of preterm birth for the general United States population (6.5 versus 12.5 percent) [
         <a href="#rid105">
          105
         </a>
         ]. Similarly, in a study that compared subsequent pregnancy outcomes among 317 patients with a history of second-trimester D&amp;E and 170 matched controls, patients with a history of prior D&amp;E delivered slightly earlier in gestation than controls (38.9 versus 39.5 weeks of gestation), but birth weight, spontaneous preterm birth, abnormal placentation, and overall rates of perinatal complications were similar between groups [
         <a href="#rid109">
          109
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication abortion
         </strong>
         – Several studies have reported similar risk of adverse obstetric outcomes among patients with medication abortion compared with no uterus instrumentation or procedural abortion [
         <a href="#rid104">
          104,107
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Rates of complications were also similar among patients undergoing medication or procedural abortion in a retrospective study including over 8000 primigravid patients [
         <a href="#rid107">
          107
         </a>
         ]. In this study, patients who had previously undergone either medication or procedural abortion had similar rates of preterm birth, low birth weight, SGA infants, or placental complications in subsequent singleton pregnancies. By contrast, in a retrospective including 173 patients undergoing second-trimester termination for fetal indications, patients with a prior medication termination (43 patients) compared with D&amp;E (130 patients) had higher rates of subsequent preterm birth (30.2 versus 6.9 percent), but the overall number of events was low [
         <a href="#rid110">
          110
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients undergoing medication termination in the first compared with second trimester appear to have similar risk pregnancy outcomes. In a retrospective study including 88,000 primigravid patients undergoing medication termination of pregnancy followed by a subsequent live birth, patients who had the procedure in the first compared with second trimester had similar risks of preterm birth, low birth weight, SGA infants, and placental complications [
         <a href="#rid108">
          108
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         The association between induced abortion and subsequent placental problems has also been studied. A report of all primigravid patients delivering in Denmark from 1980 to 1982 used data from the Danish Birth, Hospital Discharge, and Induced Abortion Registries to compare the risk of placental complications in subsequent pregnancy among 15,727 patients who underwent first-trimester termination and 46,026 patients who did not have a termination [
         <a href="#rid111">
          111
         </a>
         ]; patients were followed for 12 years. There was no difference in the risk of placenta previa, but patients with a previous termination had a slightly higher rate of retained placenta (OR 1.17, 95% CI 1.02-1.35).
        </p>
        <p class="headingAnchor" id="H3439545036">
         <span class="h2">
          Breast cancer
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy termination does not appear to be associated with an increased risk of breast cancer, although data are conflicting. A United States National Cancer Institute meta-analysis included individual data from 53 studies (83,000 females) in 16 countries and reported that the risk of breast cancer was not increased in those with a history of induced abortion (relative risk [RR] 0.93, 95% CI 0.89-0.96) [
         <a href="#rid112">
          112
         </a>
         ]. Other published studies have confirmed this conclusion [
         <a href="#rid113">
          113-116
         </a>
         ]. By contrast, a meta-analysis of 36 comparative studies in China found that a history of induced abortion was associated with an increase in the risk of breast cancer (OR 1.44, 95% CI 1.29-1.59) [
         <a href="#rid117">
          117
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2230337635">
         <span class="h2">
          Ongoing health
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pregnancy termination does not appear be associated with ongoing health issues. In a prospective study including 874 patients with undesired pregnancy, more patients who continued the pregnancy to birth reported fair to poor health compared with patients who underwent first- or second-trimester termination (27 versus 20 and 21 percent, respectively) [
         <a href="#rid118">
          118
         </a>
         ]. Self-rated health and chronic pain outcomes were similar between the first- and second-trimester abortion groups at five years.
        </p>
        <p>
         In addition, while patients may experience a variety of short- and long-term emotions, the predominant feeling reported is relief [
         <a href="#rid119">
          119
         </a>
         ]. A detailed discussion about the effects of abortion on mental health are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14193.html" rel="external">
          "Pregnancy termination and potential psychiatric outcomes"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3135901911">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109182.html" rel="external">
          "Society guideline links: Pregnancy termination"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H38">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/15750.html" rel="external">
          "Patient education: Abortion (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topic (see
         <a class="medical medical_patient" href="/z/d/html/8400.html" rel="external">
          "Patient education: Abortion (pregnancy termination) (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H39">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General issues pertaining to pregnancy termination
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Counseling
         </strong>
         – Counseling should include a nondirective discussion of alternatives (ie, continuing pregnancy with parenting or adoption) and a thorough discussion of the medical and procedural options for pregnancy termination, including the risks, benefits, and expected outcome of each. (See
         <a class="local">
          'Counseling and informed consent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Determining gestational age
         </strong>
         – Determining the correct gestational age with menstrual dating or ultrasound evaluation is a critical part of preabortion care. Menstrual dating can be used in patients in whom the date of the last menstrual period (LMP) is known with certainty and in those with regular menstrual cycles. We perform a preprocedural ultrasound prior to all second-trimester abortions.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          RhD testing and
         </strong>
         <strong>
          alloimmunization prevention
         </strong>
         – While RhD status was historically performed on all patients, evidence shows risk of alloimmunization of D-negative patients to be negligible for gestations &lt;12 weeks, and some organizations (ie, World Health Organization [WHO], Society of Family Planning [SFP], National Abortion Federation [NAF]) do
         <strong>
          not
         </strong>
         consider RhD testing a prerequisite for such patients  (
         <a class="graphic graphic_table graphicRef140124" href="/z/d/graphic/140124.html" rel="external">
          table 2
         </a>
         ). However, expert opinions vary, and the American College of Obstetrics and Gynecology (ACOG) recommends that all D-negative patients undergoing pregnancy termination receive
         <a class="drug drug_general" data-topicid="9858" href="/z/d/drug information/9858.html" rel="external">
          anti-D immune globulin
         </a>
         to prevent alloimmunization. (See
         <a class="local">
          'Laboratory testing'
         </a>
         above and
         <a class="local">
          'Alloimmunization prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Cervical dilation and preparation
         </strong>
         – Mechanical cervical dilation before uterine aspiration is generally required after 8 weeks of gestation (and sometimes before). Cervical preparation with osmotic dilators and/or prostaglandins is generally necessary after 12 to 14 weeks of gestation to dilate the cervix more slowly before dilation and evacuation (D&amp;E). (See
         <a class="local">
          'Cervical dilation and preparation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Contraception
         </strong>
         – Ovulation can occur soon after an abortion and before the onset of menses; thus, offering immediate contraception is important and can be generally initiated the day of the procedure, if desired. (See
         <a class="local">
          'Plan for contraception'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Follow-up
         </strong>
         – Follow-up depends on the gestational age at which the termination is performed and procedure type. An example of postprocedure care instructions is shown in the table  (
         <a class="graphic graphic_table graphicRef126344" href="/z/d/graphic/126344.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complications
         </strong>
         – Potential complications include hemorrhage, uterine perforation, infection, missed ectopic pregnancy, ongoing pregnancy, and retained products of conception. The overall risk of major complication (ie, hospital admission, surgery, transfusion) is low. (See
         <a class="local">
          'Complications'
         </a>
         above and
         <a class="local">
          'Ectopic pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Choice of procedure
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          First-trimester termination
         </strong>
         – For patients undergoing termination at &lt;77 days (11 weeks) of gestation, either medication or procedural abortion are appropriate options. The choice between traditional clinic-based medication abortion, no-test (ie, history-based) medication abortion, and aspiration is based on gestational age, eligibility, availability, and patient preference. Patients who place value on avoiding surgery or anesthesia and who are willing to accept more discomfort and awareness of blood and tissue loss may opt for a medication abortion. Patients who place a high value on completing the procedure in one visit are more likely to choose aspiration abortion. Eligible patients (eg, known LMP, no risk factors for ectopic pregnancy  (
         <a class="graphic graphic_table graphicRef82282" href="/z/d/graphic/82282.html" rel="external">
          table 1
         </a>
         ), no history of hemorrhagic disorders) who desire medication abortion may opt for telemedicine or self-managed abortion. (See
         <a class="local">
          'First trimester'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Second-trimester termination
         </strong>
         – Similar to first-trimester abortion, second-trimester procedures can be performed with induction (medication) or surgery (D&amp;E). How to choose between procedure types, procedure setting (eg, outpatient facility, labor and delivery unit), and the relative outcomes of medication and procedural termination in the second trimester are discussed in detail separately. (See
         <a class="local">
          'Second trimester'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14194.html" rel="external">
          "Overview of second-trimester pregnancy termination", section on 'Choosing dilation and evacuation versus induction termination'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H13359723">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Lee P Shulman, MD, and Frank W Ling, MD, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rioux C, Weedon S, London-Nadeau K, et al. Gender-inclusive writing for epidemiological research on pregnancy. J Epidemiol Community Health 2022; 76:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bearak J, Popinchalk A, Ganatra B, et al. Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019. Lancet Glob Health 2020; 8:e1152.
          </a>
         </li>
         <li class="breakAll">
          Guttmacher Institute Abortion Provider Census, 2022: https://www.guttmacher.org/article/2022/06/long-term-decline-us-abortions-reverses-showing-rising-need-abortion-supreme-court (Accessed on November 03, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kortsmit K, Jatlaoui TC, Mandel MG, et al. Abortion Surveillance - United States, 2018. MMWR Surveill Summ 2020; 69:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thompson KMJ, Sturrock HJW, Foster DG, Upadhyay UD. Association of Travel Distance to Nearest Abortion Facility With Rates of Abortion. JAMA Netw Open 2021; 4:e2115530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones RK, Jerman J. Abortion Incidence and Service Availability In the United States, 2014. Perspect Sex Reprod Health 2017; 49:17.
          </a>
         </li>
         <li class="breakAll">
          Parental Consent and Notification Laws. Planned Parenthood. Available at: https://www.plannedparenthood.org/learn/teens/stds-birth-control-pregnancy/parental-consent-and-notification-laws (Accessed on September 21, 2021).
         </li>
         <li class="breakAll">
          The State Abortion Policy Landscape One Year Post-Roe. Guttmacher Institute. https://www.guttmacher.org/2023/06/state-abortion-policy-landscape-one-year-post-roe (Accessed on October 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           White K, Sierra G, Lerma K, et al. Association of Texas' 2021 Ban on Abortion in Early Pregnancy With the Number of Facility-Based Abortions in Texas and Surrounding States. JAMA 2022; 328:2048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Addante AN, Eisenberg DL, Valentine MC, et al. The association between state-level abortion restrictions and maternal mortality in the United States, 1995-2017. Contraception 2021; 104:496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gordon MR, Coverdale J, Chervenak FA, McCullough LB. Undue burdens created by the Texas Abortion Law for vulnerable pregnant women. Am J Obstet Gynecol 2022; 226:529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crear-Perry J, Hassan A, Daniel S. Advancing Birth Equity in a Post-Dobbs US. JAMA 2022; 328:1689.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rader B, Upadhyay UD, Sehgal NKR, et al. Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision. JAMA 2022; 328:2041.
          </a>
         </li>
         <li class="breakAll">
          Questions and Answers on Mifeprex. US Food and Drug Administration. Available at: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/questions-and-answers-mifeprex (Accessed on January 07, 2022).
         </li>
         <li class="breakAll">
          MIFEPREX® (Mifepristone) Tablets, 200 mg: Prescriber Agreement Form. Danco Laboratories. Available at: https://form.jotform.com/223535677345059 (Accessed on January 27, 2023).
         </li>
         <li class="breakAll">
          Prescriber Agreement Form: Mifepristone Tablets, 200 mg. GenBioPro. Available at: https://genbiopro.com/wp-content/uploads/2019/05/GenBioPro-Prescriber-Agreement-Form.pdf (Accessed on January 27, 2023).
         </li>
         <li class="breakAll">
          https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-mifepristone-medical-termination-pregnancy-through-ten-weeks-gestation (Accessed on January 06, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schummers L, Darling EK, Dunn S, et al. Abortion Safety and Use with Normally Prescribed Mifepristone in Canada. N Engl J Med 2022; 386:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schonberg D, Wang LF, Bennett AH, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception 2014; 90:480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond EG, Bracken H. Early medical abortion without prior ultrasound. Contraception 2015; 92:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bracken H, Clark W, Lichtenberg ES, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol. BJOG 2011; 118:17.
          </a>
         </li>
         <li class="breakAll">
          2022 Clinical Policy Guidelines for Abortion Care. National Abortion Federation. https://prochoice.org/providers/quality-standards/ (Accessed on October 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins—Gynecology, Society of Family Planning. Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225. Obstet Gynecol 2020; 136:e31. Reaffirmed 2023.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization. Abortion Care Guideline (2022). https://apps.who.int/iris/bitstream/handle/10665/349316/9789240039483-eng.pdf?sequence=1&amp;isAllowed=y (Accessed on April 08, 2022).
         </li>
         <li class="breakAll">
          Mifeprex (mifepristone) Information. US Food and Drug Administration. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111323.htm (Accessed on March 30, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robson SC, Kelly T, Howel D, et al. Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS). Health Technol Assess 2009; 13:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman D, Grindlay K, Buchacker T, et al. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol 2011; 118:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Porter Erlank C, Lord J, Church K. Acceptability of no-test medical abortion provided via telemedicine during Covid-19: analysis of patient-reported outcomes. BMJ Sex Reprod Health 2021; 47:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fix L, Seymour JW, Sandhu MV, et al. At-home telemedicine for medical abortion in Australia: a qualitative study of patient experiences and recommendations. BMJ Sex Reprod Health 2020; 46:172.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman DA, Grindlay K, Buchacker T, et al. Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa. Am J Public Health 2013; 103:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrenreich K, Marston C. Spatial dimensions of telemedicine and abortion access: a qualitative study of women's experiences. Reprod Health 2019; 16:94.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grindlay K, Lane K, Grossman D. Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study. Womens Health Issues 2013; 23:e117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ehrenreich K, Kaller S, Raifman S, Grossman D. Women's Experiences Using Telemedicine to Attend Abortion Information Visits in Utah: A Qualitative Study. Womens Health Issues 2019; 29:407.
          </a>
         </li>
         <li class="breakAll">
          Clinical policy guidelines for abortion care. National Abortion Federation 2020. Available at: https://prochoice.org/store/clinical-policy-guidelines/ (Accessed on July 23, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin Summary, Number 225. Obstet Gynecol 2020; 136:855.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol 2012; 120:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreau C, Trussell J, Desfreres J, Bajos N. Medical vs. surgical abortion: the importance of women's choice. Contraception 2011; 84:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Costescu D, Guilbert E, Bernardin J, et al. Medical Abortion. J Obstet Gynaecol Can 2016; 38:366.
          </a>
         </li>
         <li class="breakAll">
          https://societyfp.org/wp-content/uploads/2023/10/WeCountReport_10.16.23.pdf.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fiastro AE, Zheng Z, Ruben MR, et al. Telehealth vs In-Clinic Medication Abortion Services. JAMA Netw Open 2023; 6:e2331900.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiken AR, Digol I, Trussell J, Gomperts R. Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland. BMJ 2017; 357:j2011.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman D, Baum SE, Andjelic D, et al. A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study. PLoS One 2018; 13:e0189195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Footman K, Keenan K, Reiss K, et al. Medical Abortion Provision by Pharmacies and Drug Sellers in Low- and Middle-Income Countries: A Systematic Review. Stud Fam Plann 2018; 49:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman D, Holt K, Peña M, et al. Self-induction of abortion among women in the United States. Reprod Health Matters 2010; 18:136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Conway GA, Slocumb JC. Plants used as abortifacients and emmenagogues by Spanish New Mexicans. J Ethnopharmacol 1979; 1:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Honigman B, Davila G, Petersen J. Reemergence of self-induced abortions. J Emerg Med 1993; 11:105.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris LH, Grossman D. Complications of Unsafe and Self-Managed Abortion. N Engl J Med 2020; 382:1029.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ngo TD, Park MH, Free C. Safety and effectiveness of termination services performed by doctors versus midlevel providers: a systematic review and analysis. Int J Womens Health 2013; 5:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. Obstet Gynecol 2015; 126:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen JT, Astley SJ, Morgan E, Nichols MD. Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study. Contraception 1999; 59:153.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gatter M, Cleland K, Nucatola DL. Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015; 91:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen MJ, Creinin MD. Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol 2015; 126:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleland K, Creinin MD, Nucatola D, et al. Significant adverse events and outcomes after medical abortion. Obstet Gynecol 2013; 121:166.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyay UD, Desai S, Zlidar V, et al. Incidence of emergency department visits and complications after abortion. Obstet Gynecol 2015; 125:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu N, Ray JG. Short-Term Adverse Outcomes After Mifepristone-Misoprostol Versus Procedural Induced Abortion : A Population-Based Propensity-Weighted Study. Ann Intern Med 2023; 176:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts SCM, Upadhyay UD, Liu G, et al. Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions. JAMA 2018; 319:2497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hyland P, Raymond EG, Chong E. A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months. Aust N Z J Obstet Gynaecol 2018; 58:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gambir K, Garnsey C, Necastro KA, Ngo TD. Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: a systematic review and meta-analysis in response to COVID-19. BMJ Glob Health 2020; 5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohn JE, Snow JL, Simons HR, et al. Medication Abortion Provided Through Telemedicine in Four U.S. States. Obstet Gynecol 2019; 134:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grossman D, Grindlay K. Safety of Medical Abortion Provided Through Telemedicine Compared With In Person. Obstet Gynecol 2017; 130:778.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond E, Chong E, Winikoff B, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception 2019; 100:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Endler M, Lavelanet A, Cleeve A, et al. Telemedicine for medical abortion: a systematic review. BJOG 2019; 126:1094.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aiken A, Lohr PA, Lord J, et al. Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study. BJOG 2021; 128:1464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reynolds-Wright JJ, Johnstone A, McCabe K, et al. Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic. BMJ Sex Reprod Health 2021; 47:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomperts RJ, Jelinska K, Davies S, et al. Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services. BJOG 2008; 115:1171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerestes C, Murayama S, Tyson J, et al. Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models. Contraception 2021; 104:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Upadhyay UD, Raymond EG, Koenig LR, et al. Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study. JAMA Intern Med 2022; 182:482.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mark A, Foster AM, Grossman D, et al. Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee. Contraception 2019; 99:265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hollenbach SJ, Cochran M, Harrington A. "Provoked" feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age. Contraception 2019; 100:142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horvath S, Luning Prak ET, Schreiber CA. A highly sensitive flow cytometry protocol shows fetal red blood cell counts in first-trimester maternal circulation well below the threshold for Rh sensitization. Contraception 2018; 98:332.
          </a>
         </li>
         <li class="breakAll">
          Abortion care guideline. National Institute for Health and Care Excellence 2019. Available at: https://www.nice.org.uk/guidance/ng140 (Accessed on July 23, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horvath S, Huang ZY, Koelper NC, et al. Induced Abortion and the Risk of Rh Sensitization. JAMA 2023; 330:1167.
          </a>
         </li>
         <li class="breakAll">
          Abortion care guideline, World Health Organization, Geneva 2022.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horvath S, Goyal V, Traxler S, Prager S. Society of Family Planning committee consensus on Rh testing in early pregnancy. Contraception 2022; 114:1.
          </a>
         </li>
         <li class="breakAll">
          National Abortion Federation. 2022 clinical policy guidelines for abortion care. https://prochoice.org/providers/quality-standards/.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstet Gynecol 2017; 130:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fung KFK, Eason E. No. 133-Prevention of Rh Alloimmunization. J Obstet Gynaecol Can 2018; 40:e1.
          </a>
         </li>
         <li class="breakAll">
          2013 Clinical Policy Guidelines. National Abortion Federation. Available at: https://www.prochoice.org/wp-content/uploads/2013NAFCPGsforweb.pdf (Accessed on June 03, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris E. Online Abortion Care Training Now Available for Ob-Gyn Residents. JAMA 2023; 330:905.
          </a>
         </li>
         <li class="breakAll">
          Reproductive Health Leaders Launch Innovative Platform to Ensure Resident Access to Abortion Education. American College of Obstetricians and Gynecologists, 2023. https://www.acog.org/news/news-releases/2023/08/reproductive-health-leaders-launch-platform-to-ensure-resident-access-to-abortion-education#:~:text=The%20PACE%20curriculum%20will%20help,with%20the%20care%20they%20need.%E2%80%9D (Accessed on September 14, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steier JA, Bergsjø P, Myking OL. Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy. Obstet Gynecol 1984; 64:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Billieux MH, Petignat P, Anguenot JL, et al. Early and late half-life of human chorionic gonadotropin as a predictor of persistent trophoblast after laparoscopic conservative surgery for tubal pregnancy. Acta Obstet Gynecol Scand 2003; 82:550.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mock P, Chardonnens D, Stamm P, et al. The apparent late half-life of human chorionic gonadotropin (hCG) after surgical treatment for ectopic pregnancy. A new approach to diagnose persistent trophoblastic activity. Eur J Obstet Gynecol Reprod Biol 1998; 78:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Midgley AR Jr, Jaffe RB. Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery. J Clin Endocrinol Metab 1968; 28:1712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jarlenski M, Hutcheon JA, Bodnar LM, Simhan HN. State Medicaid Coverage of Medically Necessary Abortions and Severe Maternal Morbidity and Maternal Mortality. Obstet Gynecol 2017; 129:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kerns J, Steinauer J. Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131. Contraception 2013; 87:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borgatta L, Chen AY, Reid SK, et al. Pelvic embolization for treatment of hemorrhage related to spontaneous and induced abortion. Am J Obstet Gynecol 2001; 185:530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steinauer JE, Diedrich JT, Wilson MW, et al. Uterine artery embolization in postabortion hemorrhage. Obstet Gynecol 2008; 111:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grimes DA, Schulz KF, Cates WJ Jr. Prevention of uterine perforation during curettage abortion. JAMA 1984; 251:2108.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Achilles SL, Reeves MF, Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception 2011; 83:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond EG, Grossman D, Weaver MA, et al. Mortality of induced abortion, other outpatient surgical procedures and common activities in the United States. Contraception 2014; 90:476.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bartlett LA, Berg CJ, Shulman HB, et al. Risk factors for legal induced abortion-related mortality in the United States. Obstet Gynecol 2004; 103:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raymond EG, Grimes DA. The comparative safety of legal induced abortion and childbirth in the United States. Obstet Gynecol 2012; 119:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990; 76:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darney PD, Nakamura-Pereira M, Regan L, et al. Maternal Mortality in the United States Compared With Ethiopia, Nepal, Brazil, and the United Kingdom: Contrasts in Reproductive Health Policies. Obstet Gynecol 2020; 135:1362.
          </a>
         </li>
         <li class="breakAll">
          Advancing Women’s Health through Medical Education: A Systems Approach in Family planning and Abortion, Landy U, Darney P, Steinauer J (Eds), Cambridge University Press, 2021. p.371.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulmann A, Silvestre L, Chemama L, et al. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women. Acta Obstet Gynecol Scand 1992; 71:278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards J, Carson SA. New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation. Am J Obstet Gynecol 1997; 176:1101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Centers for Disease Control (CDC). Ectopic pregnancy--United States, 1988-1989. MMWR Morb Mortal Wkly Rep 1992; 41:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogue CJ, Cates W Jr, Tietze C. Impact of vacuum aspiration abortion on future childbearing: a review. Fam Plann Perspect 1983; 15:119.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hogue CJ, Cates W Jr, Tietze C. The effects of induced abortion on subsequent reproduction. Epidemiol Rev 1982; 4:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atrash HK, Hogue CJ. The effect of pregnancy termination on future reproduction. Baillieres Clin Obstet Gynaecol 1990; 4:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah PS, Zao J, Knowledge Synthesis Group of Determinants of preterm/LBW births. Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses. BJOG 2009; 116:1425.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saccone G, Perriera L, Berghella V. Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2016; 214:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kalish RB, Chasen ST, Rosenzweig LB, et al. Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome. Am J Obstet Gynecol 2002; 187:882.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider D, Halperin R, Langer R, et al. Abortion at 18-22 weeks by laminaria dilation and evacuation. Obstet Gynecol 1996; 88:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Männistö J, Mentula M, Bloigu A, et al. Medical versus surgical termination of pregnancy in primigravid women--is the next delivery differently at risk? A population-based register study. BJOG 2013; 120:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Männistö J, Mentula M, Bloigu A, et al. Medical termination of pregnancy during the second versus the first trimester and its effects on subsequent pregnancy. Contraception 2014; 89:109.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson JE, Grobman WA, Haney E, Casele H. Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications. Int J Gynaecol Obstet 2007; 96:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Little SE, Janiak E, Bartz D, Smith NA. Second trimester dilation and evacuation: a risk factor for preterm birth? J Perinatol 2015; 35:1006.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou W, Nielsen GL, Larsen H, Olsen J. Induced abortion and placenta complications in the subsequent pregnancy. Acta Obstet Gynecol Scand 2001; 80:1115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beral V, Bull D, Doll R, et al. Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries. Lancet 2004; 363:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michels KB, Xue F, Colditz GA, Willett WC. Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study. Arch Intern Med 2007; 167:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reeves GK, Kan SW, Key T, et al. Breast cancer risk in relation to abortion: Results from the EPIC study. Int J Cancer 2006; 119:1741.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman E, Kotsopoulos J, Lubinski J, et al. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. Breast Cancer Res 2006; 8:R15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Committee on Gynecologic Practice. ACOG Committee Opinion No. 434: induced abortion and breast cancer risk. Obstet Gynecol 2009; 113:1417. Reaffirmed 2021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huang Y, Zhang X, Li W, et al. A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females. Cancer Causes Control 2014; 25:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ralph LJ, Schwarz EB, Grossman D, Foster DG. Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study. Ann Intern Med 2019; 171:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rocca CH, Kimport K, Roberts SC, et al. Decision Rightness and Emotional Responses to Abortion in the United States: A Longitudinal Study. PLoS One 2015; 10:e0128832.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3313 Version 59.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35764388" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Gender-inclusive writing for epidemiological research on pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32710833" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32710833" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33237897" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Abortion Surveillance - United States, 2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34228128" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Association of Travel Distance to Nearest Abortion Facility With Rates of Abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094905" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Abortion Incidence and Service Availability In the United States, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094905" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Abortion Incidence and Service Availability In the United States, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28094905" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Abortion Incidence and Service Availability In the United States, 2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318197" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Association of Texas' 2021 Ban on Abortion in Early Pregnancy With the Number of Facility-Based Abortions in Texas and Surrounding States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33781761" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The association between state-level abortion restrictions and maternal mortality in the United States, 1995-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34954218" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Undue burdens created by the Texas Abortion Law for vulnerable pregnant women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318120" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Advancing Birth Equity in a Post-Dobbs US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318194" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318194" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318194" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318194" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36318194" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Estimated Travel Time and Spatial Access to Abortion Facilities in the US Before and After the Dobbs v Jackson Women's Health Decision.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34879191" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Abortion Safety and Use with Normally Prescribed Mifepristone in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25152258" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25916975" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Early medical abortion without prior ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21091926" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21091926" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone-misoprostol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804884" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804884" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32804884" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin, Number 225.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906334" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Randomised preference trial of medical versus surgical termination of pregnancy less than 14 weeks' gestation (TOPS).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21775845" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Effectiveness and acceptability of medical abortion provided through telemedicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33602718" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acceptability of no-test medical abortion provided via telemedicine during Covid-19: analysis of patient-reported outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32665231" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : At-home telemedicine for medical abortion in Australia: a qualitative study of patient experiences and recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23153158" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Changes in service delivery patterns after introduction of telemedicine provision of medical abortion in Iowa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31269958" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Spatial dimensions of telemedicine and abortion access: a qualitative study of women's experiences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23410620" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Women's and providers' experiences with medical abortion provided through telemedicine: a qualitative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31109883" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Women's Experiences Using Telemedicine to Attend Abortion Information Visits in Utah: A Qualitative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31109883" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Women's Experiences Using Telemedicine to Attend Abortion Information Visits in Utah: A Qualitative Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32976374" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Medication Abortion Up to 70 Days of Gestation: ACOG Practice Bulletin Summary, Number 225.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23090524" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Extending outpatient medical abortion services through 70 days of gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21843684" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Medical vs. surgical abortion: the importance of women's choice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27208607" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Medical Abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27208607" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Medical Abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37656461" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Telehealth vs In-Clinic Medication Abortion Services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28512085" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Self reported outcomes and adverse events after medical abortion through online telemedicine: population based study in the Republic of Ireland and Northern Ireland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29320513" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : A harm-reduction model of abortion counseling about misoprostol use in Peru with telephone and in-person follow-up: A cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29508948" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Medical Abortion Provision by Pharmacies and Drug Sellers in Low- and Middle-Income Countries: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21111358" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Self-induction of abortion among women in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/232204" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Plants used as abortifacients and emmenagogues by Spanish New Mexicans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8445179" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Reemergence of self-induced abortions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32160664" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Complications of Unsafe and Self-Managed Abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23323024" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Safety and effectiveness of termination services performed by doctors versus midlevel providers: a systematic review and analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241252" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10382077" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Outcomes of suction curettage and mifepristone abortion in the United States. A prospective comparison study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25592080" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26241251" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Mifepristone With Buccal Misoprostol for Medical Abortion: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23262942" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Significant adverse events and outcomes after medical abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25560122" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Incidence of emergency department visits and complications after abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36592459" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Short-Term Adverse Outcomes After Mifepristone-Misoprostol Versus Procedural Induced Abortion : A Population-Based Propensity-Weighted Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29946727" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Association of Facility Type With Procedural-Related Morbidities and Adverse Events Among Patients Undergoing Induced Abortions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29603139" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : A direct-to-patient telemedicine abortion service in Australia: Retrospective analysis of the first 18 months.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33380413" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Effectiveness, safety and acceptability of medical abortion at home versus in the clinic: a systematic review and meta-analysis in response to COVID-19.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31306317" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Medication Abortion Provided Through Telemedicine in Four U.S. States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28885427" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Safety of Medical Abortion Provided Through Telemedicine Compared With In Person.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31170384" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30869829" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Telemedicine for medical abortion: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33605016" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Effectiveness, safety and acceptability of no-test medical abortion (termination of pregnancy) provided via telemedicine: a national cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33542062" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Telemedicine medical abortion at home under 12 weeks' gestation: a prospective observational cohort study during the COVID-19 pandemic.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18637010" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe services.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33789080" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Provision of medication abortion in Hawai'i during COVID-19: Practical experience with multiple care delivery models.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35311911" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Outcomes and Safety of History-Based Screening for Medication Abortion: A Retrospective Multicenter Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30867121" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Foregoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation's Clinical Policies Committee.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30980826" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : "Provoked" feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : A highly sensitive flow cytometry protocol shows fetal red blood cell counts in first-trimester maternal circulation well below the threshold for Rh sensitization
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : A highly sensitive flow cytometry protocol shows fetal red blood cell counts in first-trimester maternal circulation well below the threshold for Rh sensitization
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37750879" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Induced Abortion and the Risk of Rh Sensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37750879" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Induced Abortion and the Risk of Rh Sensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35872236" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Society of Family Planning committee consensus on Rh testing in early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35872236" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Society of Family Planning committee consensus on Rh testing in early pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28742673" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Practice Bulletin No. 181: Prevention of Rh D Alloimmunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29274715" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : No. 133-Prevention of Rh Alloimmunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29274715" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : No. 133-Prevention of Rh Alloimmunization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37610774" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Online Abortion Care Training Now Available for Ob-Gyn Residents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37610774" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Online Abortion Care Training Now Available for Ob-Gyn Residents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6462569" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Human chorionic gonadotropin in maternal plasma after induced abortion, spontaneous abortion, and removed ectopic pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12780426" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Early and late half-life of human chorionic gonadotropin as a predictor of persistent trophoblast after laparoscopic conservative surgery for tubal pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9605458" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The apparent late half-life of human chorionic gonadotropin (hCG) after surgical treatment for ectopic pregnancy. A new approach to diagnose persistent trophoblastic activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5749054" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Regulation of human gonadotropins. II. Disappearance of human chorionic gonadotropin following delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28383380" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : State Medicaid Coverage of Medically Necessary Abortions and Severe Maternal Morbidity and Maternal Mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23218863" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Management of postabortion hemorrhage: release date November 2012 SFP Guideline #20131.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11568773" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Pelvic embolization for treatment of hemorrhage related to spontaneous and induced abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18378747" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Uterine artery embolization in postabortion hemorrhage.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6708260" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Prevention of uterine perforation during curettage abortion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21397086" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25152259" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Mortality of induced abortion, other outpatient surgical procedures and common activities in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051566" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Risk factors for legal induced abortion-related mortality in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22270271" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : The comparative safety of legal induced abortion and childbirth in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2359559" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Complications of first-trimester abortion: a report of 170,000 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459428" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Maternal Mortality in the United States Compared With Ethiopia, Nepal, Brazil, and the United Kingdom: Contrasts in Reproductive Health Policies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32459428" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Maternal Mortality in the United States Compared With Ethiopia, Nepal, Brazil, and the United Kingdom: Contrasts in Reproductive Health Policies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1322621" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue. Study in 16,369 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9166176" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : New technologies permit safe abortion at less than six weeks' gestation and provide timely detection of ectopic gestation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1640927" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Ectopic pregnancy--United States, 1988-1989.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6347709" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Impact of vacuum aspiration abortion on future childbearing: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6754410" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : The effects of induced abortion on subsequent reproduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2225607" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : The effect of pregnancy termination on future reproduction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19769749" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Induced termination of pregnancy and low birthweight and preterm birth: a systematic review and meta-analyses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26743506" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Prior uterine evacuation of pregnancy as independent risk factor for preterm birth: a systematic review and metaanalysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12388969" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Impact of midtrimester dilation and evacuation on subsequent pregnancy outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8752250" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Abortion at 18-22 weeks by laminaria dilation and evacuation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23126244" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Medical versus surgical termination of pregnancy in primigravid women--is the next delivery differently at risk? A population-based register study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24332746" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Medical termination of pregnancy during the second versus the first trimester and its effects on subsequent pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17196205" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Mid-trimester dilation and evacuation with laminaria does not increase the risk for severe subsequent pregnancy complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26491851" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Second trimester dilation and evacuation: a risk factor for preterm birth?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11846708" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Induced abortion and placenta complications in the subsequent pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15051280" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Breast cancer and abortion: collaborative reanalysis of data from 53 epidemiological studies, including 83?000 women with breast cancer from 16 countries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17452545" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Induced and spontaneous abortion and incidence of breast cancer among young women: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16646050" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Breast cancer risk in relation to abortion: Results from the EPIC study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16563180" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19461458" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : ACOG Committee Opinion No. 434: induced abortion and breast cancer risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24272196" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : A meta-analysis of the association between induced abortion and breast cancer risk among Chinese females.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31181576" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Self-reported Physical Health of Women Who Did and Did Not Terminate Pregnancy After Seeking Abortion Services: A Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26154386" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Decision Rightness and Emotional Responses to Abortion in the United States: A Longitudinal Study.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
